Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
E414104-2mg
|
2mg |
2
|
$181.90
|
|
|
E414104-5mg
|
5mg |
2
|
$343.90
|
|
|
E414104-10mg
|
10mg |
2
|
$583.90
|
|
|
E414104-25mg
|
25mg |
2
|
$1,029.90
|
|
|
E414104-50mg
|
50mg |
2
|
$1,716.90
|
|
|
E414104-100mg
|
100mg |
2
|
$2,952.90
|
|
ATR Selective Inhibitors
| Synonyms | BAY 1895344 hydrochloride | BAY-1895344 HCl | 2-[(3R)-3-methyl-4-morpholinyl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-Naphthyridine hydrochloride |
|---|---|
| Specifications & Purity | Moligand™, ≥98% |
| Biochemical and Physiological Mechanisms | Elimusertib (BAY-1895344) hydrochloride is a potent, highly selective and orally available ATR inhibitor with an IC50 of 7 nM. |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Grade | Moligand™ |
| Product Description |
Information Elimusertib (BAY-1895344) hydrochloride is a potent, highly selective and orally availableATRinhibitor with an IC50 of 7 nM. Targets ATR (Cell-free assay) 7 nM In vitro BAY 1895344 is shown to be a very potent and highly selective ATR inhibitor (IC50 = 7 nM), which potently inhibits proliferation of a broad spectrum of human tumor cell lines (median IC50 = 78 nM). In cellular mechanistic assays BAY 1895344 potently inhibits hydroxyurea-induced H2AX phosphorylation (IC50 = 36 nM). In vivo BAY 1895344 reveals significantly improved aqueous solubility, bioavailability across species and no activity in the hERG patch-clamp assay. It also demonstrates very promising efficacy in monotherapy in DNA damage deficient tumor models as well as combination treatment with DNA damage inducing therapies. BAY 1895344 exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models of different indications that are characterized by DDR deficiencies, inducing stable disease in ovarian and colorectal cancer or even complete tumor remission in mantle cell lymphoma models. |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jun 26, 2025 | E414104 | |
| Certificate of Analysis | Oct 19, 2022 | E414104 | |
| Certificate of Analysis | Oct 19, 2022 | E414104 | |
| Certificate of Analysis | Oct 19, 2022 | E414104 | |
| Certificate of Analysis | Oct 19, 2022 | E414104 | |
| Certificate of Analysis | Oct 19, 2022 | E414104 | |
| Certificate of Analysis | Oct 19, 2022 | E414104 |
| Solubility | Solubility (25°C) In vitro DMSO: 82 mg/mL (199.08 mM); Water: 82 mg/mL (199.08 mM); Ethanol: 82 mg/mL (199.08 mM); |
|---|---|
| Sensitivity | Moisture sensitive |